Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: The results of the Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study reported
by Dr Schwartz and colleagues1 show that
data on statins in acute coronary syndromes (ACS) need careful interpretation.
Results of the MIRACL study showed no benefit on clinical end points (ie,
death, nonfatal myocardial infarction, and cardiac arrest) but did show a
reduction in symptomatic ischemic episodes requiring hospitalization. These
results likely overstate the benefits of statin therapy, as patients who underwent
percutaneous coronary intervention (PCI) during the trial period were excluded
from the primary combined end point.
Wierzbicki AS, Mikhaildis DP, Reynolds TR. Atorvastatin for Acute Coronary Syndromes. JAMA. 2001;286(5):532-535. doi:10.1001/jama.286.5.532